Emergency Medicine Cardiac Research and Education Group


CRUSADE
CRUSADE Quality Improvement Initiative

Launched in 2001, CRUSADE is a national quality improvement initiative, designed to increase the practice of evidence-based medicine for patients diagnosed with non-ST segment elevation acute coronary syndromes (NSTE ACS) (i.e., unstable angina or NSTE myocardial infarction).

Through a continuous cycle of data collection, performance feedback and quality improvement interventions, over 500 participating sites in the US are consistently improving the standard of care for patients with NSTE ACS. Because of the dedication of the participating hospitals to this mission, over 200,000 cases have been submitted to the CRUSADE database. For more information visit the CRUSADE website.

In 2007, a milestone occurred. Duke Clinical Research Institute and its CRUSADE leadership joined forces with the American College of Cardiology Foundation's National Cardiovascular Data Registry (NCDR™) to launch a new initiative to improve the safety and outcomes for patients with ACS through the development of NCDR-ACTION™. This initiative will combine the data collection and quality reporting features of two leading national ACS registries to create the largest and most comprehensive national cardiovascular patient database ever developed. For more information visit the NCDR-ACTION Registry™ visit the website or call 800-257-4737 for more information.




Clinical Utility of C-Reactive Protein Measured at Admission, Hospital Discharge, and 1 Month Later to Predict Outcome in Patients With Acute Coronary Disease: The RISCA (Recurrence and Inflammation in the Acute Coronary Syndromes) Study



J Am Coll Cardiol 2008;51:2339–46. View citation

Objectives: This study was designed to prospectively determine, in patients with an acute coronary syndrome, whether the inflammatory marker, C-reactive protein (CRP), measured at hospital admission, discharge, and 1 month later has incremental value to predict outcomes at 1 year.

Background The clinical utility of CRP measurements in patients with acute coronary syndromes remains uncertain. Limitations of previous studies have been retrospective design and incomplete adjustment for readily available clinical prognosticators.

Methods The CRP marker was measured at admission, hospital discharge, and 1 month later in consecutive patients hospitalized for acute coronary syndromes in 8 tertiary and secondary hospitals. The primary outcome was a composite of death, nonfatal myocardial infarction (MI), and unstable angina (UA) with electrocardiogram (ECG) changes at 1 year.

Results A total of 1,210 patients, age 62  12 years, 64% with acute myocardial infarction (MI) and 36% with unstable angina (UA), were recruited. At 1 year, the primary outcome occurred in 142 patients (11.7%) and included 58 deaths (4.8%), 79 nonfatal MIs (6.5%), and 26 UA episodes with ECG changes (2.1%). The unadjusted odds ratios (ORs) (95% confidence intervals) of CRP values at admission, hospital discharge, and 1 month later for the occurrence of the primary outcome were 1.20 (1.06 to 1.36), 0.98 (0.85 to 1.14), and 1.23 (1.00 to 1.50), respectively. After multivariate adjustment, ORs were 1.04 (0.91 to 1.20), 0.90 (0.77 to 1.06), and 1.12 (0.93 to 1.34), respectively. The individual components of the primary outcome were also not independently associated with any of the 3 CRP measurements.

Conclusions The modest predictive ability of CRP following admission for an acute coronary syndrome disappeared after adjusting for common clinical variables. This large prospective study does not support the incremental value of measuring CRP in this clinical setting.




General navigation: Home | Member roster | Consultation | Our history | Contact
News & Events: Literature news archives | EM and related events
Education: Symposium monographs | CME monographs | Articles & Print | Multimedia
Publications: Member publications | Monographs

Legal information

EMCREG™ - International
Department of Emergency Medicine
University of Cincinnati College of Medicine
ML 0769, Room 6107
231 Albert Sabin Way
Cincinnati, Ohio 45267-0769

Fell free to contact us toll-free at 1-866-4EMCREG (436-2734)



Advanced Search

28 January 2010
Study results show that the TIMI risk score predicts outcomes in in emergency department with suspected ACS.
28 January 2010
Serial measurement of NT-proBNP predicts new-onset heart failure and cardiovascular mortality in elderly.
15 January 2010
Individual risk profiling of ACS patients could optimize therapeutic treatment choices.
15 January 2010
Results of the PLATO trial show that the reversible P2Y12 inhibitor ticagrelor reduces death and cardiovascular events compared with clopidogrel therapy in ACS patients.
5 January 2010
Study shows that high sensitive cardiac troponin I level is a useful prognostic marker of mortality in chronic heart failure patients.
23 December 2009
The largest and most comprehensive meta-analysis ever concludes that CRP is unlikely to be a causal factor for cardiovascular disease.
16 December 2009
Research shows that a substantial number of STEMI patients still receive fibrinolytic therapy at PCI capable centers.
11 December 2009
Denmark researchers report in Lancet that relative risk for hospitalization for bleeding increased with all drug combinations and with each additional drug used.
3 December 2009
Researchers report that prehospital triage significantly reduces treatment delay and improves outcomes in STEMI patients who undergo PCI.
30 November 2009
Researchers report that the to reperfusion, beginning with symptom onset time, determines the extent of reversible myocardial injury in STEMI patients undergoing PCI.
19 November 2009
Data presented at the AHA 2009 Scientific Sessions shows that dabigatran when added to dual anti-platelet therapy results in a “low and acceptable bleeding rate” in AMI patients.
19 November 2009
A must-read update for the management of acute coronary syndrome.
19 November 2009
Data presented at the AHA 2009 Scientific Sessions indicates that CT angiography in the emergency room can successfully triage at-risk chest-pain patients faster and cheaper than standard of care testing.
19 November 2009
Recent meta-analysis reveals that high-risk STEMI patients given adjunctive glycoprotein (GP) IIb/IIIa inhibitor therapy and undergo primary angioplasty have a reduced risk for death.
NEWS ARCHIVES:
©Copyright EMCREG-International™. All rights reserved